Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
University of Padua
U.O.C. Oncology 2
Istituto Oncologico Veneto, IOV - IRCSS
Head, Breast Group
Medical Oncology Department
Centre Eugene Marquis UNICANCER
Chief, Breast Medicine Service
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Senior Clinical Editor
Associate Director, Scientific Services
Senior Director, Global Medical Education, Europe
Senior Director, Educational Strategy
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for medical oncologists and other healthcare providers who care for patients with metastatic breast cancer around the world.
This program has been made available online.
From Clinical Care Options (CCO), on-demand Webcast with Lee Schwartzberg, MD, FACP, and Ruth O’Regan, MD, on optimal treatment of breast cancer brain metastases
Expert video from live CCO Webinar on using immune checkpoint inhibitors and antibody–drug conjugates for early-stage through metastatic TNBC
Commentary by Dr. Kevin Kalinsky: Sequencing checkpoint inhibitors and sacituzumab govitecan in advanced TNBC with vs without BRCA mutation, from CCO
Downloadable slideset with key data from the 2020 SABCS Virtual Symposium from Clinical Care Options (CCO)